Finasteride vs. Minoxidil: The Comparison Is the Wrong Question

Framing these two as rivals is like asking whether you should use a fire extinguisher or a smoke alarm.

They address different parts of the same problem through unrelated mechanisms. Finasteride slows the process destroying your follicles. Minoxidil stimulates the follicles you still have. Which is why, in dermatology practice, the answer for most men isn't one or the other — it's both, started as early as possible.

Understanding why requires knowing what's actually happening on your scalp.

What androgenetic alopecia actually is

Male pattern hair loss isn't hair falling out. It's hair getting smaller.

Each follicle cycles through a growth phase (anagen, lasting years), a brief transition (catagen), and a resting phase (telogen) before shedding and starting over. In androgenetic alopecia, this cycle is progressively disrupted by a hormone.

Testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is a considerably more potent androgen — it binds the androgen receptor with roughly five times the affinity of testosterone.

In genetically susceptible follicles, DHT binding triggers miniaturization. With each cycle, the anagen phase shortens and the follicle produces a slightly finer, shorter, less pigmented hair. Terminal hair becomes vellus hair — the fine, near-invisible hair on the rest of your body. Eventually the follicle stops producing anything at all and fibroses.

Two things follow that explain nearly everything about treatment:

First, susceptibility is genetic and regional. Follicles on the top and front of the scalp carry a genetically determined sensitivity to DHT. The follicles at the back and sides don't. This is why the pattern is a pattern, and why hair transplantation works — DHT-resistant follicles moved to the crown remain resistant.

Second, and this is the one that matters most: miniaturization is progressive and eventually irreversible. A miniaturized-but-living follicle can be revived. A follicle that has fully fibrosed cannot. Every treatment discussed here works better the earlier it's started, and none of them regrow hair from a scalp that's been smooth for a decade.

That single fact should drive the decision more than any comparison between drugs. The most common regret in hair loss treatment is not choosing wrong — it's waiting.

One caveat before proceeding: not all hair loss is androgenetic. Thyroid disease, iron deficiency, telogen effluvium after illness or major stress, alopecia areata, and certain medications all cause hair loss with different treatments. Diffuse thinning across the whole scalp, patchy circular loss, scalp pain or scaling, or rapid onset all warrant evaluation rather than an assumption.

Finasteride: reducing the signal

What it does. Finasteride inhibits type 2 5-alpha reductase, reducing the conversion of testosterone to DHT. At 1 mg daily it lowers serum DHT by roughly 70% and scalp DHT by about 60–70%. Less DHT means less miniaturization pressure — and some follicles that were miniaturizing but still viable recover.

Effectiveness. This is the most effective medical treatment available for male pattern hair loss. In the pivotal trials, about 83% of men had no further visible loss at two years (versus 28% on placebo) and around two-thirds saw measurable regrowth; in five-year follow-up, about 90% had held or improved. Preventing further loss is the primary win; regrowth is a bonus that varies considerably by how early you start.

Timeline. Nothing visible for 3–6 months. Meaningful assessment at 12 months. Some men continue improving through 24 months. This is slow, and impatience causes more discontinuation than side effects do.

Side effects — what the trials show. In the randomized trials, sexual side effects (decreased libido, erectile dysfunction, reduced ejaculate volume) were reported by about 3.8% of men on finasteride versus 2.1% on placebo. That's a small absolute difference, and the substantial placebo rate is itself informative — a meaningful share of reported effects occur in men taking nothing.

Then there's the harder conversation. Post-finasteride syndrome describes persistent sexual, cognitive, and mood symptoms continuing after stopping the drug. It is genuinely contested. The controlled trial data doesn't demonstrate it. The reported cases are real, sometimes severe, and difficult to explain away entirely. Regulators including the FDA have required label updates reflecting reports of persistent sexual dysfunction and depression.

Putting it together: for the overwhelming majority of men, finasteride is well tolerated and side effects resolve on stopping. A small number report persistent symptoms, the mechanism isn't understood, and we cannot currently predict who. That's an uncomfortable amount of uncertainty, and you're entitled to it before deciding rather than after. If you notice mood changes or sexual side effects, that's a reason to contact your prescriber, not to push through.

Other things worth knowing:

• Finasteride lowers PSA by roughly 50%. Tell any physician checking your PSA — otherwise a meaningful reading can look reassuring.
• It's contraindicated in pregnancy. Finasteride can cause genital abnormalities in a male fetus. Women who are or may become pregnant should not handle crushed or broken tablets; coated whole tablets are considered safe to handle.
• Effects are maintenance-dependent. Stop, and DHT returns to baseline within weeks; hair gained is generally lost over the following 6–12 months.
• Dutasteride inhibits both type 1 and type 2 5-alpha reductase and lowers DHT more, with evidence of greater efficacy. It's approved for prostate enlargement in the US and used off-label for hair, with a longer half-life and a correspondingly longer commitment.

Topical finasteride: what you should be told before you use it

Topical finasteride is a legitimate option, and a lot of men do well on it. It's also routinely sold on a claim that isn't supported — that because it goes on your scalp rather than down your throat, it carries no systemic risk. That claim is the problem, not the product.

Here is what you should be told.

Topical does not mean non-systemic. Finasteride is absorbed through the skin into the bloodstream. How much depends on the formulation, the vehicle, the concentration, and how much you apply. Systemic exposure is generally lower than with an oral tablet — that's the rationale for the approach — but "lower" is not "none," and the same side effects remain possible.

There is no FDA-approved topical finasteride product. Oral finasteride is approved; every topical version is a compounded preparation, which means it has not been evaluated by the FDA for safety, effectiveness, or manufacturing quality. That isn't a reason to avoid compounded medicine, which serves real clinical purposes. It is a reason to know what you're using and where it was made.

The FDA has flagged adverse events with these products. On April 22, 2025, the agency issued an alert describing 32 adverse event reports received between 2019 and 2024 — erectile dysfunction, decreased libido, testicular pain, anxiety, depression, suicidal ideation, brain fog, fatigue, and insomnia, along with local irritation, redness and burning. In most of the reported cases, symptoms persisted after the product was stopped. The FDA specifically noted that some of those consumers had been told there was no risk because the product was topical.

Thirty-two reports across six years, against very large usage, is a low reported rate — and adverse event reporting is passive and undercounts. Neither of those facts tells you your personal risk. What they tell you is that the "topical means risk-free" claim is not true, and that you're entitled to decide with that on the table.

There is a transfer risk to other people in your household, particularly women who are or may become pregnant. Finasteride can cause genital abnormalities in a male fetus. Let the product dry fully, wash your hands, and keep application away from shared pillows and towels.

What to ask before starting. Which pharmacy compounds it, and is that facility state-licensed and inspected. What concentration you're getting. What testing is done on the batch. And what the plan is if you notice mood or sexual side effects — the answer should be "contact us and we'll reassess," not "push through."

A provider who volunteers all of this before you ask is doing it right. One who tells you a topical carries no systemic risk is repeating the exact claim the FDA called out.

Minoxidil: stimulating what's left

What it does — and how much we actually know. Minoxidil was developed as an oral antihypertensive in the 1970s. Patients grew hair. The mechanism for hair growth is still not completely understood, which is unusual for a drug in use this long.

The leading explanations: it opens ATP-sensitive potassium channels, causing vasodilation and improved perfusion to the follicle; it prolongs the anagen growth phase and shortens telogen; and it appears to shift miniaturized follicles back toward producing terminal hair.

Critically, it does nothing about DHT. It doesn't slow the underlying process — it stimulates growth despite it. Which is exactly why it pairs well with finasteride rather than competing with it.

Why some people are non-responders. Minoxidil is a prodrug. It has to be converted to its active form, minoxidil sulfate, by a scalp enzyme called sulfotransferase (SULT1A1). Enzyme activity varies substantially between individuals — and people with low scalp sulfotransferase activity respond poorly regardless of how faithfully they apply it. This is the actual explanation behind "minoxidil didn't work for me," and it's a real biochemical difference, not a compliance failure. Assays for sulfotransferase activity exist, though they aren't yet in routine use.

Effectiveness. Topical 5% produces moderate regrowth in a meaningful share of users and slows loss in more. It's generally less effective than finasteride for male pattern loss, and it's the more effective option for female pattern loss — where DHT is a smaller part of the story.

Timeline and the shedding phase. Expect an initial increase in shedding at around weeks 2–8. This alarms people into quitting, which is the worst possible response, because it's a good sign: minoxidil pushes resting follicles into a new growth phase, and the old hair has to be released first. It settles. Visible improvement takes 4–6 months; judge at 12.

Side effects. Topical: scalp irritation, dryness, and flaking — often from the propylene glycol in liquid formulations rather than the drug, which is why the foam is better tolerated. Unwanted facial hair growth if it runs or transfers, particularly onto the forehead or via a pillowcase.

Oral low-dose minoxidil (typically 0.25–5 mg daily) has become an increasingly common off-label option, and it sidesteps the scalp sulfotransferase problem for some non-responders. It is a systemic cardiovascular drug: fluid retention, ankle swelling, increased heart rate, and — rarely — pericardial effusion. It requires prescriber oversight and is not appropriate for everyone.

Like finasteride, it's maintenance-dependent. Stop, and gains are lost over the following months.

Side by side

What a well-built regimen looks like

For established androgenetic alopecia, current dermatologic practice is generally combination therapy, because the mechanisms are complementary and combination studies consistently outperform either agent alone.

A reasonable structure:

1. Confirm the diagnosis. Pattern, timeline, family history, and labs where the picture is atypical — thyroid function, ferritin, vitamin D. Diffuse or patchy loss needs a different evaluation.
2. Finasteride to slow the cause — after a real conversation about side effects, not a checkbox.
3. Minoxidil to stimulate growth, foam if liquid irritates.
4. Consider adjuncts. Ketoconazole shampoo has modest supporting evidence, likely through anti-inflammatory and mild anti-androgenic effects. Microneedling shows benefit in combination with minoxidil in several trials. Low-level laser therapy has FDA clearance and modest evidence. Platelet-rich plasma has mixed evidence with highly variable protocols.
5. Photograph the baseline. Same lighting, same angles, same time of day. Memory is unreliable over 12 months and standardized photos are the only reliable way to judge.
6. Give it a year before deciding it failed.

For women

The picture differs meaningfully.

Topical minoxidil (2% solution or 5% foam) is FDA-approved for female pattern hair loss and is first-line.

Finasteride is not approved for women and is contraindicated in pregnancy or in anyone who might become pregnant, because of the risk of genital abnormalities in a male fetus. It's used off-label in some postmenopausal women under specialist supervision.

Female pattern loss also warrants a broader workup — thyroid disease, iron deficiency, polycystic ovary syndrome, and the hormonal transition of perimenopause all contribute, and treating an underlying cause often matters more than treating the scalp.

The bottom line

The comparison you came for has a slightly unsatisfying answer: for most men with male pattern loss, both, started as early as you're willing.

Finasteride is the more effective single agent because it addresses the mechanism. Minoxidil adds growth stimulation the follicles can still respond to. Neither is a cure, both require indefinite use, and both work far better on follicles that are miniaturizing than on ones that are gone.

Which brings it back to the reserve idea, unexpectedly literally. You have a finite number of viable follicles. Treatment doesn't create new ones — it protects the ones you still have. The value of acting early isn't impatience; it's that the asset you're protecting is depleting while you decide.

---

Frequently asked questions

Can I use minoxidil without finasteride? Yes, and it's the standard approach for women. In men with male pattern loss it's usually the less effective choice alone, because the underlying DHT-driven process continues unopposed.

Will I lose the hair if I stop? Yes, with both. Gains are lost over roughly 6–12 months and loss resumes where it would have been. These are ongoing treatments.

Is topical finasteride safer than oral? Systemic exposure is generally lower, which is the whole rationale, but lower isn't none — the FDA's April 2025 alert documented systemic side effects with compounded topical products. It's a reasonable option chosen with open eyes; it is not a way to get the benefit with no risk, and anyone telling you otherwise is repeating a claim the FDA specifically called out.

How long before I know if it's working? Six months minimum for any signal; twelve months to judge properly. Take standardized photographs at the start.

Minoxidil made me shed more. Should I stop? Almost certainly not. Increased shedding at weeks 2–8 is expected and reflects follicles being pushed into a new growth phase. It settles. If it's still worsening past three months, talk to your prescriber.

Does finasteride cause permanent side effects? Trial data doesn't demonstrate it; persistent case reports exist and have prompted label updates. The best current answer is that the risk appears small, is not well characterized, and cannot currently be predicted in advance. You're entitled to weigh that yourself.